DK0610336T3 - Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse - Google Patents

Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse

Info

Publication number
DK0610336T3
DK0610336T3 DK92922537T DK92922537T DK0610336T3 DK 0610336 T3 DK0610336 T3 DK 0610336T3 DK 92922537 T DK92922537 T DK 92922537T DK 92922537 T DK92922537 T DK 92922537T DK 0610336 T3 DK0610336 T3 DK 0610336T3
Authority
DK
Denmark
Prior art keywords
interleukin
treatment
pct
inhibitory compound
neurological conditions
Prior art date
Application number
DK92922537T
Other languages
Danish (da)
English (en)
Inventor
Gareth Roberts
Nancy Jane Rothwell
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919123161A external-priority patent/GB9123161D0/en
Priority claimed from GB919125670A external-priority patent/GB9125670D0/en
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of DK0610336T3 publication Critical patent/DK0610336T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK92922537T 1991-10-31 1992-11-02 Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse DK0610336T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919123161A GB9123161D0 (en) 1991-10-31 1991-10-31 Treatment of neurological conditions
GB919125670A GB9125670D0 (en) 1991-11-30 1991-11-30 Treatment of neurogical conditions
PCT/GB1992/002023 WO1993008820A1 (en) 1991-10-31 1992-11-02 Treatment of neurological conditions by an interleukin-1 inhibiting compound

Publications (1)

Publication Number Publication Date
DK0610336T3 true DK0610336T3 (da) 2002-07-22

Family

ID=26299779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92922537T DK0610336T3 (da) 1991-10-31 1992-11-02 Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse

Country Status (10)

Country Link
US (1) US6090775A (de)
EP (1) EP0610336B1 (de)
JP (1) JP3623501B2 (de)
AT (1) ATE214939T1 (de)
AU (3) AU2884592A (de)
CA (1) CA2122596C (de)
DE (1) DE69232516T2 (de)
DK (1) DK0610336T3 (de)
ES (1) ES2173871T3 (de)
WO (2) WO1993008820A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
ATE270550T1 (de) * 1995-04-07 2004-07-15 Teijin Ltd Wirkstoff zum schutz für organ oder gewebe
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US20030040660A1 (en) * 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
WO2003022213A2 (en) * 2001-09-06 2003-03-20 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
CN101133084A (zh) * 2004-12-02 2008-02-27 多曼蒂斯有限公司 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法
EP1957537A2 (de) * 2005-12-01 2008-08-20 Domantis Limited Kompetitive domänenantikörperformate, die an den interleukin-1-rezeptor vom typ 1 binden
JP2012515164A (ja) * 2009-01-09 2012-07-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜障害を処置するための治療組成物
HUE063115T2 (hu) 2010-07-29 2023-12-28 Buzzard Pharmaceuticals AB Kiméra I-es típusú IL-1 receptor antagonisták
US20140308239A1 (en) 2013-03-13 2014-10-16 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
CA2058952A1 (en) * 1989-06-13 1990-12-14 Nabil Hanna Monokine activity interference
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases

Also Published As

Publication number Publication date
DE69232516D1 (de) 2002-05-02
ATE214939T1 (de) 2002-04-15
EP0610336A1 (de) 1994-08-17
WO1993008820A1 (en) 1993-05-13
US6090775A (en) 2000-07-18
DE69232516T2 (de) 2002-10-31
EP0610336B1 (de) 2002-03-27
AU7648296A (en) 1997-02-13
CA2122596A1 (en) 1993-05-13
ES2173871T3 (es) 2002-11-01
JPH07505608A (ja) 1995-06-22
WO1993008819A1 (en) 1993-05-13
JP3623501B2 (ja) 2005-02-23
CA2122596C (en) 2008-06-03
AU2884592A (en) 1993-06-07
AU2804192A (en) 1993-06-07

Similar Documents

Publication Publication Date Title
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DK0610336T3 (da) Behandling af neurologiske tilstande ved hjælp af en interleukin-1-hæmmende forbindelse
SE9604793D0 (sv) New polymorphs
DE69904576D1 (de) Zur behandlung von cmv infektionen geeignete 1,3,4-thiadiazole
DK1334731T3 (da) Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
DK0897726T3 (da) Antipruritisk middel
ATE302005T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ES2113652T3 (es) Pamoato de risperidona.
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
ATE184594T1 (de) Sulfonamidderivate als aspartylprotease- inhibitoren
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DE59400489D1 (de) Fungizide Wirkstoffkombinationen
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
DK0772603T3 (da) Substituerede pyrimidinforbindelser og deres anvendelse
BR9606547A (pt) Novos derivados de pirimidona com atividade fungicida
BR0113590A (pt) 7-oxo-piridopirimidinas
AU7713891A (en) Use of substituted 1,2,4-triazinediones
DK0935461T3 (da) Adamantanaminderivater til bekæmpelse af virus fra Borna viridae familien
ITMI920955A1 (it) Idrogeli di tipo polietereammidoamminico come materiali eparinizzabili
PT1642576E (pt) Utilização de derivados de pirrole para combate da ansiedade
MX9304075A (es) Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
FI953002A0 (fi) Menetelmä kroonisen eturauhastulehduksen hoitamiseksi 17beta-N-monosubstituoiduilla karbamoyyli-4-atsa-5alfa-androst-1-en-3-oneilla
DE59303446D1 (de) Neue bis-phenyl-hexene
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE59308900D1 (de) (-)-metrifonat enthaltendes arzneimittel